Editas Medicine (EDIT)
(Real Time Quote from BATS)
$3.05 USD
-0.03 (-0.97%)
Updated Nov 3, 2025 09:34 AM ET
3-Hold of 5 3
F Value C Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EDIT 3.05 -0.03(-0.97%)
Will EDIT be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for EDIT based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for EDIT
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates
Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report?
EDIT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates
Other News for EDIT
Stochastic Buy Signal appears for EDIT after 2.33% move
Gene editing therapy companies rise on word of streamlined FDA approval process
FDA to speed up gene editing therapy approvals, Bloomberg reports
FDA to speed up gene editing therapy approvals, Bloomberg reports
EDIT forms MACD Bearish Centerline Cross on October 30